Clinical Trial Search

Primary: the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 3-8 — 36.2; 37.8 percentage of participants

Primary: Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores — -0.04; -0.06; -0.08; -0.06 LogMAR…

Primary: Peak Post-prandial Venous Glucose Levels — 98; 76 mg/dL — p=0.05

Primary: Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/Milliliter (mL) at Week 48 Using the Missing, Switch, Discontinuation Equals Failure (MSDF)…

Primary: Number of Participants With Adverse Events (AEs) — 5; 6; 2; 6 Participants

Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants

Primary: CAPS Total Score Analysis Among Participants Completing at Least One Follow-up Assessment. — 77.2; 78.0; 67.5; 71.0 score on scale — p=.48

Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03

Primary: Change in Insulin Resistance — 7.38; 6.89; 6.73; 6.28 HOMA-IR Index

Primary: Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen — 31.00; 28.51; 25.31; 52.38 hour*microgram per milliliter (h*mcg/mL)

Primary: Objective Response Rate (ORR) of Pembrolizumab + Chemotherapy + Epacadostat Versus Pembrolizumab + Chemotherapy + Placebo — 26.4; 44.8 percentage of participants…

Primary: Lens Movement — 0; 0; 0; 3 Number of eyes

Primary: Feasibility of Patient Recruitment — 54 Participants

Primary: Number of Participants With Unscheduled Use of Healthcare — 61; 65 Participants

Primary: Neurocognitive Performance — 4.5; 6.1; 7.6 t-score change from baseline